Efficacy of remission-induction regimens for ANCA-associated vasculitis. - Wikidata - awgldk - TriplyDB

Efficacy of remission-induction regimens for ANCA-associated vasculitis.

Efficacy of remission-induction regimens for ANCA-associated vasculitis.

http://www.wikidata.org/entity/Q34037683

about

Interventions for renal vasculitis in adults Recent advances in understanding and treating vasculitis Granulomatosis With Polyangiitis in Otolaryngologist Practice: A Review of Current Knowledge New developments in the genetics, pathogenesis, and therapy of IgA nephropathy Lupus nephritis: the evolving role of novel therapeutics Multimorbidity and evidence generation Current and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis)Updates in ANCA-associated vasculitis The immunopathology of ANCA-associated vasculitis Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment Inaugural Symposium on Advanced Surgical Techniques in Adult Airway Reconstruction: Proceedings of the North American Airway Collaborative (NoAAC).Long-lived plasma cells in autoimmunity: lessons from B-cell depleting therapy.Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy.Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis.Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.Immunosuppressive Medications.Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement Pauci-immune glomerulonephritis in children: a clinicopathologic study of 21 patients.Successful use of Rituximab in a patient with recalcitrant multisystemic eosinophilic granulomatosis with polyangiitis Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.Linking classification and therapeutic management of vasculitides.Comparative investigation of respiratory tract involvement in granulomatosis with polyangiitis between PR3-ANCA positive and MPO-ANCA positive cases: a retrospective cohort study.Successful Combination Therapy with Rituximab and Glucocorticoids for Autoimmune Optic Neuropathy Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?Neutrophil-Related Gene Expression and Low-Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Drug-induced glomerular disease: immune-mediated injury.Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis.Benefits of an expanded use of plasma exchange for anti-neutrophil cytoplasmic antibody-associated vasculitis within a dedicated clinical service.Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts.Gleaning relapse risk from B cell phenotype: decreased CD5+ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis.CC Chemokine Ligand 18 in ANCA-Associated Crescentic GN.Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis.Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function Pauci-Immune Necrotizing and Crescentic Glomerulonephritis with Membranous Lupus Nephritis, Fifteen Years after Initial Diagnosis of Secondary Membranous Nephropathy ANCA-Associated Systemic Vasculitis Presenting With Hypertrophic Spinal Pachymeningitis: A Report of 2 Cases and Review of Literature.Early Outcomes in Children With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.[Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)].

P2860

Q24187038-F01D01A7-AAAD-4FF7-933E-D5054AF61D38 Q26747046-E0C426B1-1640-4944-9016-DF06B15E363F Q26765803-CF35EACA-2EA5-4B2D-B782-8700EC829F0A Q26786248-9E2C3ED2-9FFA-4D8D-9803-AFFC169652EB Q26998390-3317F60C-F1F4-49CE-8832-5DADCEB57607 Q27014802-B6803824-C038-460C-B77F-C381A6706B16 Q27025692-051917E1-FCD0-4AEE-A496-2F0DEC3F441B Q28069897-F761ABFF-F5D1-45EA-9DAD-12642721F022 Q28391531-05380591-28AE-4BFE-A61B-0B597FDEC82B Q28607461-1D78DB6A-C9B7-4F93-989D-B230359C9D6B Q30252605-33930AEF-B645-42C8-89B2-FBD94A7F81C6 Q33412584-80B4F499-0E99-4278-B6D2-1071E6EE149E Q33630988-76A33498-32C2-48F9-B632-20F5D98649FB Q34124711-6A869579-C0C9-4E86-9925-B6C39B7E08F4 Q34377832-4FCD658E-836D-4AB8-9535-09F11C03F541 Q34484801-61B1BDF1-FF12-4F61-B09A-C7BDF5093671 Q34500502-0400C2F9-C268-47A5-A089-E57B9094F1A9 Q35065425-A8C481A2-846E-4C91-8CA3-64BAC56686C0 Q35228543-7C3F1402-6AA2-470C-BE6B-BD697410EDC7 Q35559034-B42F3E81-EC6B-4D52-A2B2-3AD7640ADF73 Q35614757-49E716BF-FF2A-417D-9545-5B908EF4E51D Q35662018-E8401AE2-9836-456D-BDDC-E252A779AB08 Q35672892-5B9BB79E-569A-449A-A97D-D82047B9E079 Q35724221-7A87AA16-715B-40E1-B6B7-823BF77644D0 Q35725735-027E9845-C1A1-4EB8-A0BE-19AA5F5D96EE Q35759180-4583F33C-95FE-4DA9-9B92-900DC042F66D Q35777619-E2A0882D-A45E-489B-AA96-487D884D1ED0 Q35798078-2B8D390E-0C6A-4BE8-84CD-CE896BF832B4 Q35816996-56910DC1-A381-4F23-9E79-FB3A61145D72 Q35835724-5F879693-03FC-4CED-9E4D-0D22AE56DDEB Q35836369-F66BF4F4-6A5E-47AA-8F48-A3B3C5BE7F82 Q35918556-5E34FBA2-CD46-473E-A76F-450F11C0BCA7 Q35946429-382CEFA3-34A6-4398-8717-889F38C18FA2 Q36003085-4E5DD0A6-A240-420F-8939-4C4A6D78CE1B Q36104863-81AF378F-9B28-463B-BE0F-E8478E4709EC Q36134791-3AB7DAB5-AA5E-42D7-B05B-87B529E55843 Q36199241-31EDFA18-1D6B-49A0-98BD-CC16D98196E7 Q36299301-6413F58F-F85C-43BA-9A5B-012DD403D511 Q36332824-2E2BAE31-1D9A-44C1-AE54-4B4D2CB47A2D Q36394613-006916A3-9C6D-48BE-9815-5C3A1CF3C6A7

P2860

Efficacy of remission-induction regimens for ANCA-associated vasculitis.

http://www.wikidata.org/entity/Q34037683

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Efficacy of remission-induction regimens for ANCA-associated vasculitis.

@ast

Efficacy of remission-induction regimens for ANCA-associated vasculitis.

@en

Efficacy of remission-induction regimens for ANCA-associated vasculitis.

@nl

type

label

Efficacy of remission-induction regimens for ANCA-associated vasculitis.

@ast

Efficacy of remission-induction regimens for ANCA-associated vasculitis.

@en

Efficacy of remission-induction regimens for ANCA-associated vasculitis.

@nl

prefLabel

Efficacy of remission-induction regimens for ANCA-associated vasculitis.

@ast

Efficacy of remission-induction regimens for ANCA-associated vasculitis.

@en

Efficacy of remission-induction regimens for ANCA-associated vasculitis.

@nl

P1433

Q34037683-72F95EA3-4018-4762-B04A-91947084DFE9

P1476

Q34037683-C88A05E7-1557-4689-A5B2-319C31FCE508

P2093

Q34037683-0BD2ED4E-9FEC-4E5D-A582-585F768BB3ED

Q34037683-1EA78248-BD53-4F18-B958-9447B53107FB

Q34037683-33D63919-2FA5-4186-9974-F5B3EB1C9019

Q34037683-35D14FD7-901D-4433-A9E7-8C23810BF867

Q34037683-3C12F36E-B90D-4887-B8E9-7D01FEEB5FE0

Q34037683-3C4C5471-FF15-4CC5-A503-482F692FB0CE

Q34037683-44019354-476A-4B91-BAFF-3AA5EC38E44C

Q34037683-51D91183-DC3D-4C65-A7A2-61E6A48A7EF0

Q34037683-59029517-BD5E-4275-BD95-447D206C38DA

Q34037683-5D34C480-1CBE-48CA-80AA-C0A9307E2964

P2860

Q34037683-1B142AB0-8A2A-48B7-A70E-C7D3463513E3

Q34037683-1B86D65D-13CA-44C4-A3FC-0EEFFE211D88

Q34037683-1B926307-0806-4C72-B4EC-712B7E10CF92

Q34037683-33E41499-C42F-4927-B753-72CAE88C0042

Q34037683-3452403B-B73C-4701-9352-13919F2BE84D

Q34037683-3D0CB292-762E-44C3-A5C4-287C45176E2B

Q34037683-6D19DBFA-69A1-4417-9EE2-5D6C0A1E411B

Q34037683-716337F9-C349-446A-A5D4-375B1D6CE3E4

Q34037683-81C2A7A1-794E-4A56-BF01-1906A784B3DE

Q34037683-92DD22BA-2A1F-49C6-9919-2D87E337D401

P304

Q34037683-E9451B6C-CDD9-47B8-BAB8-06FA13840EAF

P31

Q34037683-2DEA8D9E-E4A4-45FB-AA5F-F12AE58C6942

P356

Q34037683-42CF8EDE-AB72-4662-968B-2D85889CB740

P407

Q34037683-03242FD2-1D35-4DAF-B3A5-2984075A063E

P433

Q34037683-241EF010-BDC8-421A-9CEF-441CE85244B2

P478

Q34037683-B651C61B-036F-44EB-986B-C5078753C72D

P50

Q34037683-33ACE23B-6816-48E5-BA45-652A4CB1D2B6

P577

Q34037683-61411305-D0A7-4366-B5A8-BD8991462541

P698

Q34037683-D7C4C38B-25F7-4584-A997-C41A8E8ED8EC

P932

Q34037683-634111AA-4BAF-48C2-A120-82BCDBD35A6A

P356

P1433

The New England Journal of Medicine

P1476

Efficacy of remission-induction regimens for ANCA-associated vasculitis.

@en

P2093

Adam L Asare

http://www.w3.org/2001/XMLSchema#string

Barri J Fessler

http://www.w3.org/2001/XMLSchema#string

Brett Jepson

http://www.w3.org/2001/XMLSchema#string

Carol A Langford

http://www.w3.org/2001/XMLSchema#string

Coen Stegeman

http://www.w3.org/2001/XMLSchema#string

David Ikle

http://www.w3.org/2001/XMLSchema#string

Deborah J Phippard

http://www.w3.org/2001/XMLSchema#string

Duvuru Geetha

http://www.w3.org/2001/XMLSchema#string

E William St Clair

http://www.w3.org/2001/XMLSchema#string

Eugene Y Kissin

http://www.w3.org/2001/XMLSchema#string

P2860

Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis

Prediction of creatinine clearance from serum creatinine

Nomenclature of systemic vasculitides. Proposal of an international consensus conference

Etanercept plus standard therapy for Wegener's granulomatosis.

Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells.

Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial

Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.

A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.

P304

417-427

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1213277

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P50

Cees G M Kallenberg

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23902481

http://www.w3.org/2001/XMLSchema#string

P932

5953195

http://www.w3.org/2001/XMLSchema#string